Asahi shares mark weekly slide after cyberattack halts production
Chief Commercial Officer of Beta Bionics, Inc. (NASDAQ:BBNX), Mark Hopman, sold 848 shares of common stock on September 2, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $18.8632, with prices ranging from $18.58 to $19.09, for a total transaction value of $15,995. The stock has since risen to $20.10, showing continued momentum. According to InvestingPro data, BBNX has demonstrated strong performance with a 7.4% gain in the past week, though technical indicators suggest the stock is currently overbought.
The sale was to cover tax withholding obligations associated with the vesting of restricted stock units. Following the transaction, Hopman directly owns 33,284 shares of Beta Bionics, Inc. The company, currently valued at $819 million, maintains a strong financial position with an overall "GOOD" health score according to InvestingPro analysis, which offers 8 additional key insights about BBNX’s financial outlook and market position.
In other recent news, Beta Bionics Inc . reported its second-quarter earnings for 2025, showcasing a significant improvement in its financial performance. The company posted an earnings per share (EPS) of -$0.39, which surpassed analysts’ expectations of -$0.42. Additionally, Beta Bionics experienced a 54% year-over-year increase in net sales, reaching $23.2 million. Truist Securities responded to these results by raising its price target for Beta Bionics to $21.00 from $18.00, while maintaining a Buy rating. The company’s revenue and gross margin exceeded expectations, driven by strong new patient starts and success in the pharmacy benefit provider channel. These recent developments reflect positively on Beta Bionics’ financial health and market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.